8-K: Y-mAbs Therapeutics Unveils Positive Phase 1 Data and Expanded Radiopharmaceutical Pipeline

Y-mAbs Therapeutics, Inc. announced complete Part A data from its GD2-SADA Phase 1 Clinical Trial (Trial 1001), validating the safety and tolerability of its pretargeted radioimmunotherapy platform and outlining an expanded oncology pipeline.

Summary

• Y-mAbs Therapeutics, Inc. completed Part A of its GD2-Self-Assembly DisAssembly (SADA) Phase 1 Clinical Trial (Trial 1001) for patients with recurrent or refractory metastatic solid tumors.
• The GD2-SADA-177Lu-DOTA complex was found to be safe and well-tolerated, with no dose-limiting toxicities (DLTs) or treatment-related serious adverse events (SAEs) reported across all dosing cohorts.
• Pharmacokinetics (PK) of the GD2-SADA protein were predictable and reproducible, demonstrating a reliable correlation between dose concentration and clearance rate, which provides a roadmap for tailoring clearance intervals.
• Out of 22 patients dosed, 9 showed positive tumor uptake per protocol, making them eligible for the therapeutic stage; an expanded evaluation revealed 16 patients had tumor uptake.
• The company identified 'Proteus,' a novel universal radiohapten, through preclinical studies, which is expected to significantly improve tumor uptake and retention (showing improvements of ~465% vs ~275% ID/g AUC and 660% vs 130% ID/g AUC in different models).
• Y-mAbs plans to initiate a Trial 1001 Bridge study (Part 2A) incorporating Proteus in the first half of 2026, with data readout anticipated in the second half of 2026.
• Part B of Trial 1001, a Phase 1/2 dose escalation study, is expected to commence in the first half of 2027, with data readout in the second half of 2027.
• The company has expanded its radiopharmaceutical development pipeline to focus on high-value oncology franchise areas, including lung, women's, and gastrointestinal cancers.
• An Investigational New Drug (IND) submission for the company's first molecular imaging asset is anticipated by the end of 2025.

Sentiment

Score: 8

Explanation: The document presents strong positive clinical data validating the core technology's safety and predictable pharmacokinetics, along with a clear strategic plan for optimization and pipeline expansion into high-value oncology areas. The identified need for molecule optimization and a potential minor regulatory delay are noted but do not overshadow the overall positive progress and future outlook.

Positives

• The GD2-SADA-177Lu-DOTA complex demonstrated a safe and well-tolerated profile in Phase 1 Part A, with no DLTs or treatment-related SAEs.
• Pharmacokinetics (PK) of the GD2-SADA protein were predictable and reproducible, allowing for optimized therapeutic index through tailored clearance intervals.
• Positive tumor uptake was observed in 16 out of 22 patients in the expanded evaluation, validating the pretargeted approach in humans.
• The development of 'Proteus,' a new universal radiohapten, is expected to significantly enhance tumor uptake and retention, improving the platform's efficacy.
• Strategic expansion of the radiopharmaceutical pipeline into high-value oncology targets such as lung, women's, and gastrointestinal cancers broadens market opportunity.
• The initiation of a molecular imaging portfolio complements the therapeutic pipeline and offers additional diagnostic capabilities.

Negatives

• The initial protocol for tumor selection in Trial 1001 Part A artificially limited the assessment, excluding additional tumors that showed dose uptake from evaluation.
• Dosimetry results indicated that the initial GD2-SADA-177Lu-DOTA formulation did not reach an optimal therapeutic index, necessitating molecule optimization.
• Neuroblastoma patients (aged >16 years, with prior GD2 treatments) showed no tumor uptake in the 0/2 cases evaluated.
• A potential delay of 2-3 months may occur if the FDA recommends a new IND filing instead of an amendment for the Trial 1001 Bridge Study.

Risks

• Risks associated with the company's financial condition and the need for additional capital.
• The risk that actual results of the company's business unit realignment will not meet expectations.
• Risks inherent in development work, including potential delays or changes to the timing, cost, and success of product development activities and clinical trials, particularly difficulties in patient enrollment.
• Risks of delays in FDA and/or EU approval of drug candidates or outright failure to receive approval.
• Risks related to commercializing any approved new pharmaceutical product, including the rate and degree of market acceptance, development of sales and marketing capabilities, and failure to obtain sufficient reimbursement.
• Dependence on third parties for the conduct of clinical testing, product manufacture, and regulatory submissions.
• The company's ability to enter into collaboration or other arrangements with partners.
• Risks associated with the protection of the company's intellectual property rights.
• Risks related to macroeconomic conditions, including geopolitical conflicts (Russia-Ukraine, Israel-Hamas), international trade policies, inflation, increased interest rates, uncertain global credit and capital markets, and disruptions in banking systems.

Future Outlook

Y-mAbs plans to accelerate the clinical advancement of its Self-Assembly DisAssembly Pretargeted Radioimmunotherapy (SADA PRIT) technology platform, incorporating the new 'Proteus' radiohapten into future studies to optimize the therapeutic index. The company is strategically expanding its radiopharmaceutical pipeline into new, high-value oncology franchise areas, including lung, women's, and gastrointestinal cancers. Additionally, Y-mAbs is developing a molecular imaging portfolio, with an Investigational New Drug (IND) filing for its first asset anticipated by the end of 2025.

Management Comments

• Michael Rossi, President and CEO: "At Y-mAbs, our mission is to deliver innovative therapeutic solutions for life-threatening diseases and improve the lives of patients and their families. We are excited to provide these updates across our Radiopharmaceutical Business today, share data confirming our pretargeted approach has been validated in humans, and reiterate the potential of our platform to deliver novel products that we believe will have a meaningful impact on how we treat certain cancers. Based on today’s update, we reaffirm our commitment to accelerating the clinical advancement of our Self-Assembly DisAssembly Pretargeted radioimmunotherapy (SADA PRIT) technology platform and pipeline."
• Natalie Tucker, Radiopharmaceutical Business Unit Head: "The complete Part A data from Trial 1001 highlighted today provides further validation for our novel SADA PRIT technology platform. This data from Part A of Trial 1001 adds to the substantial learning we have developed through clinical and preclinical research regarding our SADA PRIT technology. Based on our work, we believe that SADA is a truly differentiated pretargeted platform positioned to potentially disrupt the radiopharmaceutical industry and significantly improve patient outcomes."

Industry Context

Y-mAbs is positioning its SADA PRIT platform as a potentially disruptive technology within the radiopharmaceutical industry. The company aims to overcome existing commercial utilization limitations by leveraging its proprietary technology for in vivo assembly, modular design for isotope flexibility, enhanced physician participation, and improved patient safety through optimal therapeutic dosing with minimal toxicity. The strategic expansion into lung, women's, and gastrointestinal cancers aligns with addressing significant unmet medical needs in large oncology markets, indicating a focus on high-value opportunities within the broader cancer treatment landscape.

Comparison to Industry Standards

• The document states that the SADA platform is "positioned to potentially disrupt the existing approach to Radiopharmaceuticals" and "significantly improve patient outcomes."
• It highlights the potential for "minimal off-target effects" and "optimal therapeutic dose with minimal toxicity" as advantages.
• The SADA technology was developed by researchers at Memorial Sloan Kettering Cancer Center (MSK), including Dr. Nai-Kong Cheung, and is exclusively licensed by MSK to Y-mAbs.
• However, the document does not provide specific comparisons to named competitor companies, projects, or global benchmarks in terms of clinical results or market performance.

Related Party Transactions

• The SADA technology for radioimmunotherapy was developed by researchers at Memorial Sloan Kettering Cancer Center (MSK), including Dr. Nai-Kong Cheung, and is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the technology, and Dr. Cheung has intellectual property rights and interests in the technology.

Stakeholder Impact

• Shareholders: Positive clinical data and a clear strategic pipeline expansion could lead to increased shareholder value and potential for future revenue streams from new therapeutic areas.
• Patients: The development of novel, potentially safer, and more effective cancer treatments, particularly for recurrent or refractory metastatic solid tumors, offers significant benefit.
• Physicians: The SADA platform's design aims to enhance physician participation along the treatment journey, potentially improving clinical adoption.
• Employees: Continued focus on R&D and pipeline expansion suggests stability and growth opportunities within the company.
• Creditors: Positive clinical progress and strategic growth could enhance the company's financial stability and creditworthiness.

Next Steps

• File an Investigational New Drug (IND) for the first molecular imaging asset by the end of 2025.
• Initiate CD38-SADA First Patient In (FPI) in the first half of 2025.
• Submit GD2-Diagnostic IND in the second half of 2025.
• Initiate GD2-Diagnostic FPI in the first half of 2026.
• Initiate GD2-SADA Bridge Study with the new Radiohapten (Proteus) in the first half of 2026.
• Read out data from the Trial 1001 Bridge Study with the new Radiohapten in the second half of 2026.
• Initiate the Dose Escalation Study (Trial 1001, Part B) in the first half of 2027.
• Initiate the GD2-SADA Pediatric Study (Trial 1002) in the first half of 2027.
• Read out data from the GD2-SADA Pediatric Trial (Trial 1002) in the second half of 2027.
• Read out data from the GD2-SADA Dose Escalation Study (Trial 1001, Part B) in the second half of 2027.
• Submit IND for a new target (metastatic Colorectal Cancer mCRC) in the first half of 2027.
• First Patient In (FPI) for the new therapeutic (mCRC) in the second half of 2027.

Key Dates

Recommendation

Keywords

Radiopharmaceutical, Oncology, Cancer Treatment, GD2-SADA, Radioimmunotherapy, SADA PRIT, Clinical Trial, Biopharmaceutical, Tumor Uptake, Proteus, Radiohapten, Clinical Development, Pipeline Expansion, DANYELZA, Neuroblastoma, Solid Tumors, Lung Cancer, Women's Cancers, Gastrointestinal Cancers, Molecular Imaging